New blood pressure drug Tekturna benefits heart failure patients too

A new blood pressure drug called Tekturna made by Novartis has been found to benefit heart failure patients also.

Tekturna was recently granted approval in both the U.S. and Europe. Tekturna, known generically as aliskiren, is sold under the name Rasilez in Europe.

Tekturna is the first of a new type of drug known as a renin inhibitor that experts hope will give extra benefits compared with older medicines.

John McMurray of the University of Glasgow, Scotland, says a study of 300 heart patients revealed that Tekturna was found to significantly cut levels of B-type natriuretic peptide (BNP), a biomarker associated with worsening outcomes for patients with heart problems.

The study found that Tekturna proved to be effective when given to patients even though they were already taking other types of heart medication and it was found that there was no significant excess of either hypotension (excessively low blood pressure) or kidney dysfunction.

Dr. McMurray says it is hoped that a reduction of BNP will translate into a reduction of morbidity and mortality, but that needs to be proved in a large randomised trial, which is the next step.

Heart failure effects millions of people world wide and occurs when the heart is not strong enough to maintain full circulation throughout the entire body; it is a major focus of medical research.

The results were presented at the annual meeting of the European Society of Cardiology.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Deadly high blood pressure during pregnancy is on the rise